DOJ Sues Healthpoint Over Zenaderm Marketing

Law360, New York (April 1, 2011, 7:13 PM EDT) -- The U.S. Department of Justice on Thursday accused Healthpoint Ltd. of falsely marketing the bedsore ointment Xenaderm as a prescription drug qualifying for Medicare and Medicaid reimbursement, causing the agencies to pay $90 million for an ineligible drug.

The complaint filed in the U.S. District Court for the District of Massachusetts alleges that Healthpoint violated the False Claims Act by submitting false statements regarding the eligibility of federal reimbursement for the drug Xenaderm to the Centers for Medicare and Medicaid Services.

Texas-based Healthpoint began marketing the...
To view the full article, register now.




Case Information

Case Title

United States, ex rel v. Actavis Mid-Atlantic, et al

Case Number




Nature of Suit

Other Statutory Actions


Rya W. Zobel

Date Filed

August 29, 2002


Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.